Table 1.
Clinical features of pancreatic solitary fibrous tumors
| Ref. | Age/Sex | Chief complaint(s) | Size (cm) | Location | Arterial-CT | Venous-CT | T1-MRI | T2-MRI | Tumor marker |
| Lüttges et al[13] | 50/female | Incidental | 5.5 | Body | Enhanced | Enhanced | NA | NA | Negative |
| Chatti et al[14] | 41/male | Abdominal pain | 13.0 | Body | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Gardini et al[15] | 62/female | Abdominal pain | 3.0 | Head | Enhanced | Enhanced | NA | NA | Negative |
| Miyamoto et al[10] | 41/female | Abdominal pain | 2.0 | Head-body | Enhanced | Enhanced | NA | NA | Negative |
| Kwon et al[16] | 54/male | Incidental | 4.5 | Body | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Srinivasan et al[17] | 78/female | Back pain, weight loss | 5.0 | Body | Enhanced | Enhanced | NA | NA | Negative |
| Chetty et al[18] | 67/female | Incidental | 2.6 | Head | Enhanced | Enhanced | NA | NA | Negative |
| Ishiwatari et al[19] | 58/female | Incidental | 3.0 | Head | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Sugawara et al[20] | 55/female | Incidental | 7.0 | Head | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Azadi et al[6] | 57/male | Incidental | 3.1 | Tail | Enhanced | Enhanced | Hypointense | Hyperintense | |
| Santos et al[21] | 40/male | Incidental | 3.0 | Body | NA | NA | NA | NA | Negative |
| Tasdemir et al[11] | 24/female | Epigastric pain | 18.5 | Head | Enhanced | Enhanced | NA | NA | Negative |
| van der Vorst et al[22] | 67/female | Abdominal pain | 2.8 | Head | Enhanced | NA | NA | NA | Negative |
| Chen et al[23] | 49/female | Abdominal pain | 13.0 | Head | Enhanced | Enhanced | NA | NA | Negative |
| Hwang et al[24] | 53/female | Incidental | 5.2 | Head | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Baxter et al[25] | 54/female | Abdominal pain | 3.5 | Head | NA | N.A | NA | NA | CEA, CA19-9 |
| Estrella et al[3] | 52/female | Obstructive jaundice | 15.0 | Head | Hetero-geneous | Hetero-geneous | NA | NA | Negative |
| Han et al[26] | 77/female | Jaundice | 1.5 | Head | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Murakami et al[27] | 82/male | Hypokalemia, hypertension, edema | 6.0 | Tail | Hetero-geneous | Hetero-geneous | Hypointense | Hyperintense | Negative |
| Paramythiotis et al[28] | 55/male | Abdominal pain | 3.6 | Body | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Spasevska et al[29] | 47/male | Epigastric pain and jaundice | 3.5 | Head | Enhanced | Enhanced | N.A | N.A | CA19-9 |
| Oana et al[30] | 73/male | Abdominal discomfort | 7.5 | Head | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
| Current case | 48/male | Hypoglyce-mia | 6.5 | Body | Enhanced | Enhanced | Hypointense | Hyperintense | Negative |
CT: Computed tomography; MRI: Magnetic resonance imaging; NA: Not applicable.